OCCAM Immune

Occam Immune is an Academic Research Organization providing immune monitoring solutions tailored for pharma and biotech companies conducting clinical trials

[OCCAM Immune @Occamimmune]

We are excited to launch OCCAM Immune, an Academic Research Organization providing streamlined #ImmuneMonitoring services to the pharma and biotech industry for clinical studies.

Check out the immune monitoring as a service options we provide here >>> https://t.co/CiiMvxPifd

[RareCyte, Inc. @RareCyte]

16-channel imaging of Ovarian Serous Cystadenocarcinoma, acquired on the Orion Spatial Biology platform. 🌟

Image is courtesy of Zhihong Chen and custody of Human Immune Monitoring Center, @Occamimmune, @IcahnMountSinai.

#SpatialBiology #SpatialProteomics #OvarianCancer

[OCCAM Immune @Occamimmune]

Happy Holidays from the OCCAM Immune Team! 🎄

Thank you to all our partners and supporters for an amazing year. We’re excited for what’s ahead in 2025 and look forward to continuing this journey together.

Wishing you a joyful holiday season!

#HappyHolidays #Immunology

[Emma Guttman-Yassky @EmmaGuttman]

Excited to see that I rank among the highest cited people in the field of immunology and medicine. Proud of our work! #researcher #research #immunology #medicine #mountsinai #dermatology #skin #disease #translational #eczema #allergy #alopecia #treatment #inflammation #aging

[OCCAM Immune @Occamimmune]

Excited to announce that our CEO Erik Wambre, will be presenting "Immunophenotypes of Food Allergy & Responses to Immunotherapy Across the Life Course" Friday Nov 22 at the @EAACI_HQ FAAM-EUROBAT conference in Athens, Greece!

Reach out if you'd like to meet—we’d love to connect!

[OCCAM Immune @Occamimmune]

DM if you'd like to meet the @OCCAMimmune team at the 'Next Generation Immunotherapy Discoveries' symposium Oct 3.

We'd love to introduce our custom immune profiling capabilities to investigators & industry representatives planning clinical trials of cutting-edge immunotherapy.

[Lipschultz Precision Immunology Institute @SinaiImmunol]

Join us ONLINE Oct 3 for a joint symposium hosted by @InnatePharma & @IcahnMountSinai to find out what upcoming immunotherapy strategies are envisioned by @MiriamMerad @EricVivier @EJohnWherry & more.

Don’t miss out—register now for FREE: https://t.co/dcr7oJLIsa

👇 Program 👇

[OCCAM Immune @Occamimmune]

JOIN US in-person at the 'Next Generation Immunotherapy Discoveries' Symposium, Oct 3rd in NYC, a great opportunity to meet CEO @ErikWambre & discuss cutting edge immune monitoring for clinical studies of new immunotherapies at the lunch or cocktail reception:

[Innate Pharma @InnatePharma]

25th anniversary ✨

We are thrilled to invite you to a scientific symposium on “Next Generation Immunotherapy Discoveries”, where leading scientists, physicians and professors from prestigious institutions will present the latest and greatest advances in immunotherapy.

[OCCAM Immune @Occamimmune]

@ovanoekelen @CellRepMed Explore our full range of cutting-edge technologies for immunophenotyping patient responses to new immunotherapies to reveal how they work here >>> https://t.co/TzI0FnJluy.

[OCCAM Immune @Occamimmune]

Discover how the @Occamimmune mass cytometry panel helped Samir Parekh and @ovanoekelen uncover how Iberdomide activates immune cells to fight cancer in the bone marrow of patients with relapsed/refractory #MultipleMyeloma. Study in @CellRepMed 👇

https://t.co/d9HjD9Ib1K

[OCCAM Immune @Occamimmune]

@ovanoekelen @CellRepMed Iberdomide is a CELMoD: a new class of immunomodulatory drugs for treating myeloma. We employed standardized mass cytometry to show that Iberdomide enhances effector T and NK cells, offering new mechanistic insights into how Iberdomide boosts innate and adaptive tumor immunity.

[OCCAM Immune @Occamimmune]

@AllergyEaaci By unveiling an immunotherapy's mechanism of action, our antigen-specific T cell assays pave the way for targeted & effective treatments.

More info on the cutting-edge immune monitoring services we provide to support immunotherapy clinical trials here >>> https://t.co/CiiMvxPifd

[OCCAM Immune @Occamimmune]

Check out our paper in @AllergyEaaci! Our antigen-specific T cell assays track the key changes in peanut-specific T cells during treatment, revealing the precise immune responses that underpin the immunotherapy's success in combatting #PeanutAllergy. https://t.co/9K7CanKJ4l

[OCCAM Immune @Occamimmune]

Meet @DrTomMarron, a pioneer of mechanistic clinical trials of cancer immunotherapy. Read about how Tom & @MiriamMerad's TARGET and INTERACT programs integrate immune profiling to provide actionable insights into how to treat cancer and other diseases >>> https://t.co/EDTBPcQX3U

[OCCAM Immune @Occamimmune]

At @Occamimmune, we're expanding our #ImmuneMonitoring capabilities with brand-new, state-of-the-art facilities at the heart of Manhattan.

We look forward to welcoming you to our new space at 619 West 54th St. and advancing immunotherapy and translational research together!

[Mount Sinai Tisch Cancer Center @TischCancer]

New from Samir Parekh, @ovanoekelen, and colleagues: Iberdomide increases innate and adaptive immune cell subsets in the bone marrow of patients with relapsed/refractory multiple myeloma: Cell Reports Medicine https://t.co/1IRDOCANmu
@IcahnMountSinai #MultipleMyeloma